COMMUNIQUÉS West-GlobeNewswire

VR Helps Children with Autism Develop Social, Communication Skills, New Research Shows
23/09/2024
BlueSprig Pediatrics’ research featured in Behavior Analysis in Practice highlights potential for VR to successfully reconstruct re-world scenarios within learning programs HOUSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- [...]
PeopleOne Health and RosenCare Host Grand Opening of Orlando Health Center Serving Orange County Public School Employees
23/09/2024
Celebration marks the start of a four-center expansion in the Orlando area with key local leaders in attendance ORLANDO, Fla. and PITTSBURGH, Sept. 23, 2024 (GLOBE NEWSWIRE) -- PeopleOne Health , a trailblazer in value- [...]
Route 92 Medical Announces $50 Million Series F Extension Equity Financing
23/09/2024
Funds from Novo Holdings will support global commercial expansion Novo Holdings’ Noel Jee joins Route 92 Board of Directors SAN MATEO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held [...]
Digital Utilities Ventures Reports Strong Fiscal Year 2024 - Advancing Leadership in Green Technologies
23/09/2024
MANKATO, Minn., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Digital Utilities Ventures, Inc. (OTC: DUTV), a leader in sustainable energy and environmental technologies, recently announced its financial results and corporate [...]
T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture
23/09/2024
LEXINGTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted a [...]
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
23/09/2024
WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
23/09/2024
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance – – New PK/PD results demonstrate that istisociclib given at 80mg on a 4 [...]
Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform
23/09/2024
Opportunity for significant savings in energy consumption, reduction of paper and elimination of disposable batteries for telemetry revealed in Life Cycle Assessment Amsterdam, The Netherlands and Cambridge, Mass. and [...]
Interim Results for the Six Months Ended 30 June 2024
23/09/2024
Press release OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration progressing across UK [...]
Revolutionizing Surgery: SS Innovations International Inc. Celebrates 2,000 Procedures with its SSi Mantra Surgical Robotic System
23/09/2024
FORT LAUDERDALE, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making [...]
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2
23/09/2024
MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in [...]
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
23/09/2024
BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cerevance , a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief executive officer, will [...]
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
23/09/2024
FDA confirm s that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty [...]
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
23/09/2024
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary [...]
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
23/09/2024
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster presentations of post-hoc [...]
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
23/09/2024
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET - The European Microbiome Innovation for Health [...]
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
22/09/2024
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey [...]
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
21/09/2024
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia , including TEV -‘ 749 Currently, there is no long-acting olanzapine [...]
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
21/09/2024
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia throu gh scientific and clinical advances that support optimal treatment options and decisions for [...]

Pages